Overview

This trial is active, not recruiting.

Conditions carcinoma of unknown primary origin, iris melanoma, medium/large size posterior uveal melanoma, mucosal melanoma, ocular melanoma with extraocular extension, small size posterior uveal melanoma, stage iib skin melanoma, stage iib uveal melanoma, stage iic skin melanoma, stage iiia skin melanoma, stage iiia uveal melanoma, stage iiib skin melanoma, stage iiib uveal melanoma, stage iiic skin melanoma, stage iiic uveal melanoma, stage iv skin melanoma, stage iv uveal melanoma
Treatments dec-205/ny-eso-1 fusion protein cdx-1401, laboratory biomarker analysis, neoantigen-based melanoma-poly-iclc vaccine, pharmacological study, recombinant flt3 ligand
Phase phase 2
Target FLT-3
Sponsor National Cancer Institute (NCI)
Start date April 2014
End date April 2016
Trial size 60 participants
Trial identifier NCT02129075, CITN-07-FLT3L, NCI-2014-00898, U01CA154967

Summary

This randomized phase II trial studies how well DEC-205/NY-ESO-1 fusion protein CDX-1401 (CDX-1401) and neoantigen-based melanoma-poly-ICLC vaccine (poly-ICLC) vaccine therapy work when given with or without recombinant flt3 ligand (CDX-301) in treating patients with stage IIB-IV melanoma. The cancer vaccine CDX-1401 attaches to a protein that is made in tumor cells. The vaccine helps the body recognize the tumor to fight the cancer. The CDX-301 vaccine may help the body make more of the tumor fighting cells, known as dendritic cells. The poly-ICLC vaccine stimulates the immune system and may help these dendritic cells mature so that they can recognize the tumor. It is not yet known whether CDX-1401 and poly-ICLC will work better with or without CDX-301 in treating melanoma.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Allocation randomized
Endpoint classification efficacy study
Intervention model parallel assignment
Masking open label
Primary purpose treatment
Arm
(Experimental)
Patients receive recombinant flt3 ligand SC on days -7 to -1, 1-3, and 22-28 of course 1 and on days 1-3 of course 2 only; DEC-205/NY-ESO-1 fusion protein CDX-1401 SC or ID on day 1; and poly-ICLC SC on day 1. Treatment repeats every 28 days for 4 courses in the absence of disease progression or unacceptable toxicity.
dec-205/ny-eso-1 fusion protein cdx-1401 CDX-1401
Given SC or ID
laboratory biomarker analysis
Correlative studies
neoantigen-based melanoma-poly-iclc vaccine NeoVax Melanoma Vaccine
Given SC
pharmacological study
Correlative studies
recombinant flt3 ligand CDX-301
Given SC
(Active Comparator)
Patients receive DEC-205/NY-ESO-1 fusion protein CDX-1401and poly-ICLC as in Arm I. Treatment repeats every 28 days for 4 courses in the absence of disease progression or unacceptable toxicity.
dec-205/ny-eso-1 fusion protein cdx-1401 CDX-1401
Given SC or ID
laboratory biomarker analysis
Correlative studies
neoantigen-based melanoma-poly-iclc vaccine NeoVax Melanoma Vaccine
Given SC
pharmacological study
Correlative studies

Primary Outcomes

Measure
Immune T-cell response to NY-ESO-1
time frame: Up to 12 weeks after final vaccination

Secondary Outcomes

Measure
Frequency and phenotypic character of PBMC subsets including DCs, monocyte populations, T cells, and NK cells
time frame: Up to 12 weeks after final vaccination
Immune responses to other ongoing and nascent antitumor response antigens as well as memory and chronic viral responses
time frame: Up to 12 weeks after final vaccination
Immunological response
time frame: Up to 12 weeks after final vaccination
Incidence of adverse events, graded and reported using the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0
time frame: Up to 12 weeks after final vaccination
Survival
time frame: Up to 1 year after patient's 12 week visit
Time to tumor recurrence
time frame: Up to 12 weeks after final vaccination

Eligibility Criteria

Male or female participants at least 18 years old.

Inclusion Criteria: - Patients with fully resected stage IIb through IV melanoma, with melanoma validated by histology or cytology, who have NOT received prior therapy - Patients may have had primary cutaneous, mucosal, or ocular melanoma or metastasis from an unknown primary site - Tissue should be submitted for evaluation of NY-ESO-1 expression and T-cell infiltrates; however, availability of tissue and/or positivity for NY-ESO-1 is not mandatory - Prior therapy requirements: - Prior radiation, chemotherapy or biologics NOT allowed - Not currently receiving any anticancer therapy - Eastern Cooperative Oncology Group (ECOG) performance score of 0-1 - Life expectancy of at least 6 months - Leukocytes >= 3,000/mcL - Absolute neutrophil count >= 1,000/mcL - Platelets >= 75,000/mcL - Hemoglobin > 9 g/dL - Total bilirubin < 1.5 x institutional upper limit of normal (bilirubin < 3 x institutional upper limit of normal for Gilbert's syndrome) - Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 2.5 x institutional upper limit of normal - Creatinine < 1.5 x institutional upper limit of normal OR creatinine clearance >= 60 mL/min/1.73 m^2 for patients with creatinine levels above institutional normal - The first six patients enrolled in the Flt3L arm of the study cannot be human immunodeficiency virus (HIV)-positive; after the evaluation of safety in the first 6 patients, HIV-positive patients with adequate immune function as evidenced by stable cluster of differentiation (CD)4 counts >= 350/mm^3 are allowed to participate if the following criteria are met: - Maintained on stable antiretroviral therapy with no significant drug interactions, and - No recent history of acquired immune deficiency syndrome (AIDS) indicator conditions (> 2 years from enrolling in trial), and - Physician providing patient's care for HIV must also approve of patient entering the study - Both men and women of all races and ethnic groups are eligible for this trial - Females of childbearing potential must have a negative pregnancy test within 7 days before the initiation of protocol therapy - Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control or abstinence) before study entry and for the duration of study participation; should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately; men treated or enrolled on this protocol must also agree to use adequate contraception before the study, for the duration of study participation, and 4 months after completion of CDX-1401 or CDX-301 administration - NOTE: Subjects are considered not of child bearing potential if they are surgically sterile, they have undergone a hysterectomy, bilateral tubal ligation, or bilateral oophorectomy, or they are postmenopausal; menopause is the age associated with complete cessation of menstrual cycles, menses, and implies the loss of reproductive potential; by a practical definition, it assumes menopause after 1 year without menses with an appropriate clinical profile at the appropriate age - Ability to understand and the willingness to sign a written informed consent document Exclusion Criteria: - Patients who have had cytotoxic chemotherapy, radiotherapy, interferon (IFN), or ipilimumab before entering the study - Immunosuppressive therapy within 30 days prior to initiation of protocol therapy - Steroid therapy, or steroid therapy with more than 7 consecutive days of steroids within the prior 4 weeks - The use of prednisone or equivalent < 0.125 mg/kg/day (absolute maximum of 10 mg/day) as replacement therapy is permitted - Inhaled or topical corticosteroids are permitted - Patients who are receiving any other investigational agents - Current or history of systemic autoimmune disease requiring systemic therapy - NOTE: The following will not be exclusionary: - The presence of laboratory evidence of autoimmune disease (e.g., positive ANA titer) without associated symptoms - Clinical evidence of vitiligo - Other forms of depigmenting illness - Cardiovascular disease that meets one of the following: congestive heart failure (New York Heart Association class III or IV), active angina pectoris, or recent myocardial infarction (within the last 6 months) - Cirrhosis or chronic hepatitis C virus positivity or chronic hepatitis B infection - NOTE: A positive hepatitis B serology indicative of previous immunization (i.e., hepatitis B surface antibody [HBsAb]-positive and hepatitis B core antibody [HBcAb]-negative), or a fully resolved acute hepatitis B virus infection is not an exclusion criterion - Known history of immunodeficiency disorder other than HIV-positive status - Extensive active brain disease including symptomatic brain metastases or presence of leptomeningeal disease - NOTE: Patients with brain metastasis, after definitive therapy with surgery or stereotactic radiation and stable off steroids for >= 4 weeks, are eligible - Other invasive cancers that are clinically active - Pregnancy or nursing or unwilling to take adequate birth control during therapy - NOTE: Breastfeeding should be discontinued if the mother is treated with CDX-1401 or CDX-301 and poly-ICLC - History of allergic reactions attributed to compounds of similar chemical or biologic composition to CDX-1401 or CDX-301 or poly-ICLC - Prior organ allograft or allogeneic transplantation, if the transplanted tissue is still in place - Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements - Medical or psychiatric illness that would, in the opinion of the investigator, preclude participation in the study or the ability of patients to provide informed consent for themselves - History of pulmonary disease such as emphysema or chronic obstructive pulmonary disease (COPD) (forced expiratory volume in one second [FEV1] < 60% of predicted for height and age); pulmonary function tests (PFTs) are required in patients with prolonged smoking history or symptoms of respiratory dysfunction - Vaccinations other than those given as part of this research study (with the exception of influenza vaccine) are prohibited throughout the duration of study participation - NOTE: Influenza vaccination (inactivated) is permitted during the flu season; the preferred time is 7 to 14 days after CDX-1401 administration

Additional Information

Official title A Phase II, Open-Label, Multicenter, Randomized Study of CDX-1401, a Dendritic Cell Targeting NY-ESO-1 Vaccine, in Patients With Malignant Melanoma Pre-treated With Recombinant CDX-301, a Recombinant Human Flt3 Ligand
Principal investigator Nina Bhardwaj
Description PRIMARY OBJECTIVES: I. To determine whether the immune response to cancer/testis antigen 1B (NY-ESO-1) elicited by vaccination with CDX-1401 (anti-DEC205-NY-ESO-1 fusion protein vaccine) plus polyinosinic-polycytidylic acid stabilized with poly-L-lysine and carboxymethylcellulose (poly-ICLC) is substantially increased by prior expansion in the number of circulating dendritic cells (DC) by therapy with CDX-301 (fms-related tyrosine kinase 3 ligand [Flt3L]) (recombinant flt3 ligand). SECONDARY OBJECTIVES: I. To assess the effect of the vaccine regimen on immune responses to other ongoing and nascent antitumor response antigens associated with melanoma (e.g., preferentially expressed antigen in melanoma [PRAME], melanoma antigen family A, 3 [MAGE-A3], tumor protein p53 [p53], and premelanosome protein [gp100]) as well as memory viral responses (influenza A) and chronic viral responses (cytomegalovirus [CMV], Epstein-Barr virus [EBV]). II. To assess the effect of the vaccine regimen on the frequency and phenotypic character of peripheral blood mononuclear cell (PBMC) subsets including DCs, monocyte populations, T cells, and natural killer (NK) cells. III. To assess the safety, tolerability, and clinical efficacy of the vaccine regimens. OUTLINE: Patients are randomized to 1 of 2 treatment arms. ARM I: Patients receive recombinant flt3 ligand subcutaneously (SC) on days -7 to -1, 1-3, and 22-28 of course 1 and on days 1-3 of course 2 only; DEC-205/NY-ESO-1 fusion protein CDX-1401 SC or intradermally (ID) on day 1; and poly-ICLC SC on day 1. ARM II: Patients receive DEC-205/NY-ESO-1 fusion protein CDX-1401and poly-ICLC as in Arm I. In both arms, treatment repeats every 28 days for 4 courses in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up at 4 and 12 weeks and then annually thereafter.
Trial information was received from ClinicalTrials.gov and was last updated in November 2016.
Information provided to ClinicalTrials.gov by National Cancer Institute (NCI).